–
–
One World Cannabis Ltd, a wholly owned subsidiary of Israel’s OWC Pharmaceutical Research Corp. (OTCQB: OWCP) which develops cannabinoid-based therapies targeting a variety of different indications, is implementing regulation and patient-care consultancy services in New York to further advance the application and registration of medical cannabis business licenses within the existing Medical Cannabis Program.
Yes that’s right. Israel is not only a leader in the world of high tech, but also in the innovation of the cultivation of marijuana. As more and more American states legalize medical marijuana and even marijuana just for recreational use, Israeli firms like OWC are perfectly positioned to benefit financially.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
“Our intention is to provide support to local New York businesses which intend to dispense and manufacture medical cannabis and help shepherd certifications through the Medical Cannabis Program, ” said Dr. Yehuda Baruch, One World Cannabis Director of Research and Regulatory Affairs and international authority on medical cannabis programs.
In addition to helping guide certified New York-based medical cannabis businesses through the regulatory framework and operating infrastructure, One World Cannabis is helping to institute the creation of a medical cannabis patients’ center, consisting of patient communities. The company is also offering training and educational modules for patients – as well as physicians, caregivers and researchers – to enhance the understanding of patient-focused medical cannabis programs within existing and developing U.S. markets.
OWC also plans on a collaboration with patient groups as “Americans for Safe Access”, in building and educating patients to become quality reviewers of the dispensary work and mentor other patients on how to better use medical cannabis (CTP Cannabis for Therapeutic Purposes). It is a 24/7 service and support (by phone) for the first week of use In order to help the patients counter various common side effects and thus help adherence to treatment.
“By building an infrastructure for safe care and management in using medical cannabis, we can serve as a valued partner in the process of helping medical cannabis businesses to train and educate patients, and their families, about cannabis products, treatment for medical conditions and dispensary services, ” added Dr. Baruch, who served as Head of the Israeli Ministry of Health’s Medical Cannabis Program for 10 years.
In addition to regulatory expertise, One World Cannabis has practical research knowledge in the field of medical cannabis treatment to carry out scientific investigations into the medical effects and benefits of cannabis and the development of new products based on the results of scientific studies.
“We want to become an international hub for medical cannabis information and research, while also serving as a regulation service consultancy for advancing legislation to allow further use of medical cannabis, ” added Ziv Turner, CEO of One World Cannabis Ltd.
While continuing with scientific investigations into the medical effects and benefits of cannabis and the development of new programs, One World Cannabis recently released preliminary results from the first of several contracts to conduct joint preclinical and clinical research projects on the effect of several combinations of cannabinoil (CBD), tetrahydrocannabinol (THC), and research in treatment for multiple myeloma, a highly treatment-resistant form of bone marrow cancer.
Future studies for other medical conditions are currently underway.
